↓ Skip to main content

Dove Medical Press

Article Metrics

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
41 Mendeley
Title
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
Published in
Therapeutics and Clinical Risk Management, March 2016
DOI 10.2147/tcrm.s85099
Pubmed ID
Authors

Luca Prosperini, Simona Pontecorvo

Abstract

Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. Two randomized clinical trials (Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS [DEFINE] and Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis [CONFIRM]) demonstrated significant efficacy in reducing relapse rate and radiological signs of disease activity, as seen on magnetic resonance imaging. The DEFINE study also indicated a significant effect of DMF on disability worsening, while the low incidence of confirmed disability worsening in the CONFIRM trial rendered an insignificant reduction among the DMF-treated groups when compared to placebo. DMF also demonstrated a good safety profile and acceptable tolerability, since the most common side effects (gastrointestinal events and flushing reactions) are usually transient and mild to moderate in severity. Here, we discuss the place in therapy of DMF for individuals with relapsing multiple sclerosis, providing a tentative therapeutic algorithm to manage newly diagnosed patients and those who do not adequately respond to self-injectable DMTs. Literature data supporting the potential role of DMF as a first-line therapy are presented. The possibility of using DMF as switching treatment or even as an add-on strategy in patients with breakthrough disease despite self-injectable DMTs will also be discussed. Lastly, we argue about the role of DMF as an exit strategy from natalizumab-treated patients who are considered at risk for developing multifocal progressive leukoencephalopathy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 5%
Russia 1 2%
Unknown 38 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 29%
Student > Bachelor 7 17%
Student > Master 6 15%
Unspecified 4 10%
Student > Doctoral Student 4 10%
Other 8 20%
Readers by discipline Count As %
Medicine and Dentistry 14 34%
Unspecified 7 17%
Agricultural and Biological Sciences 4 10%
Neuroscience 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Other 9 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 March 2016.
All research outputs
#6,382,781
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#337
of 922 outputs
Outputs of similar age
#96,371
of 270,777 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#12
of 58 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,777 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.